Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2010

Open Access 01-12-2010 | Research

Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer

Authors: Bulent Karabulut, Burcak Karaca, Umut Varol, Ugur Muslu, Burcu Cakar, Harika Atmaca, Aslı Kısım, Selim Uzunoglu, Ruchan Uslu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Login to get access

Abstract

Background

Ovarian cancer is the most fatal gynecologic malignancies in the world. Although, platinum based treatments are widely used, the disease becomes treatment refractory within two years, and novel treatment options should be searched. All- trans retinoic acid (ATRA) induces growth arrest, differentiation and cell death in some types of cancer cells and its combination with various anticancer agents results in enhanced cytotoxicity. Zoledronic acid is a common bisphosphonate known for its anticancer effects beyond its current use in the treatment of cancer-induced bone disease. We aimed to investigate the possible additive/synergistic effect of both agents in OVCAR-3 and MDAH-2774 ovarian cancer cell lines, since both agents show superiority to conventional cytotoxics in terms of adverse events.

Methods

XTT cell proliferation assay was used for showing cytotoxicity. For verifying apoptosis, both DNA Fragmentation by ELISA assay and caspase 3/7 activity measurement were used. OligoGeArray® which consists of 112 apoptosis related genes was used to elucidate the genetic changes within cancer cells. To validate our oligoarray results, quantitative real-time PCR was performed on four selected genes that were maximally effected by the combination treatment: lymphotoxin beta receptor (LTBR), myeloid cell leukemia-1 (MCL-1), tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A), TNFRSF1A-associated death domain protein (TRADD).

Results

We demonstrated that a novel combination of ATRA and zoledronic acid is a strong inducer of apoptotic related cell death in both ovarian cancer cells. While the combination therapy significantly induced proapoptotic genes such as tumor necrosis factor receptor superfamily (TNFRSF), TRADD and caspase 4, some of the antiapoptotic genes such as members of MCL-1, LTBR, BAG3 and Bcl-2 family members were inhibited.

Conclusions

These are the preliminary molecular results of a novel combination treatment of ATRA and zoledronic acid, with fewer side effects as compared to conventional cytotoxic agents. With additional experimental analysis, it may serve as a good option for the treatment of refractory and elderly ovarian cancer patients, for whom there exists very limited choice of treatment.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.CrossRef
2.
Ozols RF: Future directions in the treatment of ovarian cancer. Semin Oncol. 2002, 29 (1 Suppl 1): 32-42. 10.1053/sonc.2002.31594.CrossRef
3.
Amos B, Lotan R: Retinoid-sensitive cells and cell lines. Methods Enzymol. 1990, 190: 217-225. full_text.CrossRef
4.
Mangelsdorf DJ, Umesono K, Evans RM: The retinoid receptors. The Retinoids Biology Chemistry and Medicine. Edited by: Sporn MB, Roberts AB, Goodman DS. New York: Raven Pres, 1994: 319-349.
5.
Caliaro MJ, Marmouget C, Guichard S, Mazars Ph, Valette A, Moisand R, Bugat R, Jozan S: Response of four human ovarian carcinoma cell lines to all trans retinoic acid: relationship with induction of differentiation and retinoic acid receptor expression. Int J Cancer. 1994, 56: 743-748. 10.1002/ijc.2910560522.CrossRef
6.
Lotan R: Suppression of squamous cell carcinoma growth and differentiation by retinoids. Cancer Res. 1994, 54 (7 Suppl): 1987-1990.
7.
Bryan M, Pulte ED, Toomey KC, Pliner L, Pavlick AC, Saunders T, Wieder R: A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer. Invest New Drugs. 2010, Jul 2,
8.
David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM: Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies. Cancer Biol Ther. 2010,
9.
Arrieta O, González-De la Rosa CH, Aréchaga-Ocampo E, Villanueva-Rodríguez G, Cerón-Lizárraga TL, Martínez-Barrera L, Vázquez-Manríquez ME, Ríos-Trejo MA, Alvarez-Avitia MA, Hernández-Pedro N, Rojas-Marín C, De la Garza J: Randomized Phase II Trial of All-Trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-Line Treatment in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2010, Jun 14,
10.
Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MV, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ, Nanus DM: Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. J Immunother. 2007, 30 (6): 655-62. 10.1097/CJI.0b013e31805449a8.CrossRef
11.
Aebi S, Kroning R, Cenni B, Sharma A, Fink D, Weisman R, Howell SB, Christen RD: All-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells. Clin Cancer Res. 1997, 3: 2033-2038.
12.
Kucukzeybek Y, Gul MK, Cengiz E, Erten C, Karaca B, Gorumlu G, Atmaca H, Uzunoglu S, Karabulut B, Sanli UA, Uslu R: Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. J Exp Clin Cancer Res. 2008, 27: 37-10.1186/1756-9966-27-37.CrossRef
13.
Caliaro MJ, Vitaux P, Lafon C, Lochon I, Néhmé A, Valette A, Canal P, Bugat R, Jozan S: Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Br J Cancer. 1997, 75: 333-340.CrossRef
14.
Winter MC, Holen I, Coleman RE: Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008, 34: 453-475. 10.1016/j.ctrv.2008.02.004.CrossRef
15.
Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, Thorpe H: The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010, 102 (7): 1099-1105. 10.1038/sj.bjc.6605604.CrossRef
16.
Matsumotoa S, Kimura S, Segawab H, Kurodab J, Yuasab T, Satoa K, Nogawab M, Tanakaa F, Maekawab T, Wadaa H: Efficacy of the third generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer. 2005, 47: 31-39. 10.1016/j.lungcan.2004.06.003.CrossRef
17.
Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G: Repeated intermittent low-dose therapy with zoledronic acid induces an early, and sustained, and long lasting decrease of vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007, 13: 4482-4486. 10.1158/1078-0432.CCR-07-0551.CrossRef
18.
Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomized, phase 2 trial. Lancet Oncol. 2010, 11 (5): 421-428. 10.1016/S1470-2045(10)70054-1.CrossRef
19.
Gnant M, Mlineritsch B, Luschin-Ebengreuth GL, Kainberger F, Kassmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008, 9: 840-849. 10.1016/S1470-2045(08)70204-3.CrossRef
20.
Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF: Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983, 43: 5379-5388.
21.
Erten C, Karaca B, Kucukzeybek Y, Gorumlu G, Cengiz E, Gul MK, Atmaca H, Uzunoglu S, Karabulut B, Sanli UA, Uslu R: Regulation of growth factors in hormone- and drug resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. BJU Int. 2009, 104: 107-114. 10.1111/j.1464-410X.2009.08340.x.CrossRef
22.
Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs on enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55. 10.1016/0065-2571(84)90007-4.CrossRef
23.
Ashkenazi A, Holland P, Eckhardt : Ligand based Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL). J Clin Oncol. 2008, 26: 3621-3630. 10.1200/JCO.2007.15.7198.CrossRef
24.
Hsu H, Shu HB, Pan MG, Goeddel DV: TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996, 84: 299-306. 10.1016/S0092-8674(00)80984-8.CrossRef
25.
Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell. 1996, 85: 817-827. 10.1016/S0092-8674(00)81266-0.CrossRef
26.
Chopra DP, Menard RE, Januszewski J, Mattingly RR: TNF-α mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Lett. 2004, 203: 145-154. 10.1016/j.canlet.2003.09.016.CrossRef
27.
Mana SK, Aggarwal BB: All-trans-retinoic acid up regulates TNF receptors and potentiates TNF-induced activation of nuclear factors-кB, activated protein-1 and apoptosis in human lung cancer cells. Oncogene. 2000, 19: 2110-2119. 10.1038/sj.onc.1203547.CrossRef
28.
Strasser A, O'Connor L, Dixit VM: Apoptosis signaling. Annu Rev Biochem. 2000, 69: 217-245. 10.1146/annurev.biochem.69.1.217.CrossRef
29.
Adams JM, Cory S: Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci. 2001, 26: 61-66. 10.1016/S0968-0004(00)01740-0.CrossRef
30.
Lee JH, Takahashi T, Yasuhara N, Inazawa J, Kamada S, Tsujimoto Y: Bis, a Bcl-2- binding protein that synergizes with Bcl-2 in preventing cell death. Oncogene. 1999, 18: 6183-6190. 10.1038/sj.onc.1203043.CrossRef
31.
Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF, Wacheck V, Selzer E, Müllauer L, Agis H, Sillaber C, Valent P: Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood. 2007, 109: 3031-3041.
32.
Degli-Esposti MA, Davis-Smith T, Din WS, Smolak PJ, Goodwin RG, Smith CA: Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells. J Immunol. 1997, 158: 1756-1762.
33.
Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, Wortham K, Kelly R, Bottiglio C, Ding J, Griffith L, Heaney G, Silverio E, Yang W, Jarpe M, Fawell S, Reff M, Carmillo A, Miatkowski K, Amatucci J, Crowell T, Prentice H, Meier W, Violette SM, Mackay F, Yang D, Hoffman R, Browning JL: Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res. 2006, 66: 9617-9624. 10.1158/0008-5472.CAN-06-0217.CrossRef
34.
Winter MC, Holen I, Coleman RE: Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008, 34: 453-475. 10.1016/j.ctrv.2008.02.004.CrossRef
Metadata
Title
Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer
Authors
Bulent Karabulut
Burcak Karaca
Umut Varol
Ugur Muslu
Burcu Cakar
Harika Atmaca
Aslı Kısım
Selim Uzunoglu
Ruchan Uslu
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-29-102

Other articles of this Issue 1/2010

Journal of Experimental & Clinical Cancer Research 1/2010 Go to the issue

Research

Expression and clinicopathological significance of Mel-18 and Bmi-1 mRNA in gastric carcinoma

Research

Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods

Research

A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples

Research

CIP2A expression is increased in prostate cancer

Research

Expression of MDR1, HIF-1α and MRP1 in sacral chordoma and chordoma cell line CM-319

Research

The HPB-AML-I cell line possesses the properties of mesenchymal stem cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits